A5024180018- Pharmaceutical Economics and Policy
- Health Systems, Economic Evaluations, Quality of Life
- Health and Medical Studies
- Pharmaceutical studies and practices
- Pharmaceutical industry and healthcare
- Global Health Care Issues
- Vaccine Coverage and Hesitancy
- Pharmaceutical Practices and Patient Outcomes
- Pharmaceutical Quality and Counterfeiting
- Immune responses and vaccinations
- Taxation and Legal Issues
- Endodontics and Root Canal Treatments
- Artificial Intelligence in Healthcare
- Global trade and economics
- Ethics in Clinical Research
- Diverse Specialized Academic Research
- Data-Driven Disease Surveillance
- Healthcare Systems and Public Health
- Virology and Viral Diseases
- Clostridium difficile and Clostridium perfringens research
- Misinformation and Its Impacts
- Electronic Health Records Systems
- EU Law and Policy Analysis
- Biosimilars and Bioanalytical Methods
- Innovation Policy and R&D
Gesundheit Österreich
2014-2025
Public Health Institute
2021
Austrian Institute for International Affairs
2021
To analyze a sample of pharmaceutical waste drawn from household garbage in Vienna, with the aim to learn whether and which medicines end up unused normal waste. We obtained Vienna Municipal Waste Department. This was by their staff representative search October November 2009. did manual investigation contained packs loose blisters, excluded medical devices traced blisters back packs. reported information on prescription status, origin, therapeutic group, dose form, contents expiry date....
Building the European Antimicrobial Resistance Surveillance network in Veterinary medicine (EARS-Vet) was proposed to strengthen One Health antimicrobial resistance (AMR) surveillance approach.
The General Data Protection Regulation is a regulation in EU law on data protection and privacy the European Union. We aimed to provide an overview of (GDPR) enablers barriers secondary use health Europe from research we conducted Joint Action InfAct (Information for Action!) WP10 Assessing piloting interoperability public policy, as well example national-level case study experiences with GDPR Austrian COVID-19 platform.We have identified number initiatives, projects organizations that dealt...
The EU-funded project Pharmaceutical Pricing and Reimbursement Information (PPRI) offers countryspecific information on pricing reimbursement for numerous EU Member States indicators acomparativeanalysis. Thisarticlepresentsrelevantpharmaceuticalpricingandreimbursementinformationin a comparative analysis 28 countries also detailed description about the Spanish andreimbursement system.
Knowledge about the prices of medicines used in hospitals, particularly actually achieved ones, is scant. There are indications large discounts and provision cost-free to Austrian hospitals. The study aims survey official actual procured by hospitals compare them out-patient prices. Primary price collection hospital list for 12 active ingredients as end September 2009 five general Austria analysis 15 most commonly presentations. per unit differed considerably (from 1,500 Euro an oncology...
Pricing of pharmaceuticals is an all-time challenge for healthcare systems. Often public payers agree with companies on confidential managed-entry agreements (MEAs) that, e.g. foresee discounts under specific circumstances. The EURIPID Executive Committee surveyed 22 European countries, who all reported the use between pharmaceutical and payers, confirming that actual prices paid are typically lower than published list price. In 68% confidentiality MEAs required by non-disclosure clauses...
Aim: To explain the components of pharmaceutical expenditure and illustrate strengths limitations this indicator.In particular, we explore policies applied in European countries that aff ect price volume medicines.Methodology: This paper is based on a presentation held at Drug Utilization Research Group (EuroDURG)/International Society for Pharmacoepidemiology (ISPE) meeting Antwerp, Belgium 1 December 2011.The aim to raise awareness how interpret data.Updated are surveys by WHO...
Background: In the European Member States, systems for pharmaceutical pricing and reimbursement differ significantly. Amongst administration policy-makers at both national levels there is a lot of interest in different States as means learning from their experiences reimbursement. Objectives: The general objective PPRI–Project – started April 2005 - to develop network authorities institutions order improve information knowledge on enlarged Union. This should facilitate regular exchange allow...
Before the COVID-19 pandemic, a need for uniform approach to health information (HI) knowledge in population analysis across Europe was evident. The Population Health Information Research Infrastructure (PHIRI) emerged as proactive initiative strengthen European HI capacities. This article describes achievements of PHIRI, highlighting its capacity-building activities and their contribution towards sustainable strategy implementation Data Space (EHDS).